High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease
- PMID: 17028128
- PMCID: PMC1942160
- DOI: 10.1136/gut.2006.099796
High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease
Abstract
Background: It is not clear which species of bacteria may be involved in inflammatory bowel disease (IBD). One way of determining which bacteria might be likely candidates is to use culture-independent methods to identify microorganisms that are present in diseased tissues but not in controls.
Aims: (1) To assess the diversity of microbial communities of biopsy tissue using culture-independent methods; (2) to culture the bacteria found in the tissues of patients with IBD but not in the controls; (3) to identify potential virulence factors associated with cultured bacteria.
Methods: 84 biopsy specimens were collected from 15 controls, 13 patients with Crohn's disease (CD) and 19 patients with ulcerative colitis (UC) from a population-based case-control study. Ribosomal intergenic spacer analysis (RISA) was conducted to identify unique DNA bands in tissues from patients with CD and UC that did not appear in controls.
Results: RISA followed by DNA sequencing identified unique bands in biopsy specimens from patients with IBD that were classified as Escherichia coli. Targeted culture showed a significantly (p<0.05) higher number of Enterobacteriaceae in specimens from patients with IBD. The B2+D phylogenetic group, serine protease autotransporters (SPATE) and adherence factors were more likely to be associated with tissues from patients with UC and CD than with controls.
Conclusions: The abundance of Enterobacteriaceae is 3-4 logs higher in tissues of patients with IBD and the B2+D phylogenetic groups are more prevalent in patients with UC and CD. The B2+D phylogenetic groups are associated with SPATE and adherence factors and may have a significant role in disease aetiology.
Conflict of interest statement
Competing interests: None.
Comment in
-
The role of Escherichia coli in inflammatory bowel disease.Gut. 2007 May;56(5):610-2. doi: 10.1136/gut.2006.111872. Gut. 2007. PMID: 17440180 Free PMC article.
References
-
- Koutroubakis I E. Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 20052266–272. - PubMed
-
- Sartor R B. Role of commensal enteric bacteria in the pathogenesis of immune‐mediated intestinal inflammation: lessons from animal models and implications for translational research. J Pediatr Gastroenterol Nutr 200540(Suppl 1)S30–S31. - PubMed
-
- Rath H C. The role of endogenous bacterial flora: bystander or the necessary prerequisite? Eur J Gastroenterol Hepatol 200315615–620. - PubMed
-
- Bernstein C N, Wajda A, Blanchard J F. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population‐based study. Gastroenterol 2005129827–836. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical